CINECA IRIS Institutional Research Information System

FERRERO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4201
EU - Europa 3899
AS - Asia 1425
AF - Africa 57
OC - Oceania 21
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4078
CN - Cina 979
IT - Italia 548
DE - Germania 497
RU - Federazione Russa 482
IE - Irlanda 437
SE - Svezia 395
UA - Ucraina 355
FR - Francia 319
FI - Finlandia 242
KR - Corea 236
GB - Regno Unito 190
AT - Austria 154
PL - Polonia 150
CA - Canada 119
VN - Vietnam 103
IN - India 41
SN - Senegal 41
BE - Belgio 32
CH - Svizzera 16
ES - Italia 16
NL - Olanda 15
AU - Australia 14
DK - Danimarca 12
JP - Giappone 12
UZ - Uzbekistan 12
GR - Grecia 11
AR - Argentina 9
NZ - Nuova Zelanda 7
SG - Singapore 7
TR - Turchia 7
BY - Bielorussia 6
HK - Hong Kong 6
MU - Mauritius 6
CZ - Repubblica Ceca 5
MX - Messico 4
SA - Arabia Saudita 4
TW - Taiwan 4
ZA - Sudafrica 4
BN - Brunei Darussalam 3
BR - Brasile 3
EU - Europa 3
NO - Norvegia 3
DZ - Algeria 2
ID - Indonesia 2
MY - Malesia 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BO - Bolivia 1
CO - Colombia 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MW - Malawi 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
TN - Tunisia 1
UG - Uganda 1
Totale 9624
Salva come PNG Salva come JPEG
Città #
Beijing 761
Chandler 685
Dublin 436
Houston 401
Fairfield 253
Jacksonville 214
Villeurbanne 197
Medford 185
Ann Arbor 175
Torino 154
Princeton 153
Vienna 152
Wilmington 137
Nyköping 133
Woodbridge 129
Warsaw 127
Dearborn 122
Ashburn 104
Seattle 85
Cambridge 82
Milan 70
Toronto 67
Dong Ket 63
Pisa 56
Fremont 49
San Mateo 47
Redwood City 43
Boardman 40
Boston 36
Verona 36
Hefei 32
Regensburg 32
Guangzhou 30
Turin 30
Brussels 28
Nanjing 24
Norwalk 24
Lachine 23
London 23
Düsseldorf 20
San Diego 20
Ottawa 17
Mountain View 16
Berlin 15
New York 14
Falls Church 13
Hangzhou 12
Nürnberg 12
San Jose 12
Chengdu 11
Gorzów Wielkopolski 11
Duncan 10
Seoul 10
Buenos Aires 9
Chennai 9
Kunming 9
Napoli 9
Poznan 9
Nanchang 8
Silver Spring 8
Changchun 7
Elsternwick 7
Munich 7
Shanghai 7
Upper Marlboro 7
Amsterdam 6
Athens 6
Central District 6
Detroit 6
Fuzhou 6
Hebei 6
Istanbul 6
Philadelphia 6
Phoenix 6
Zhengzhou 6
Alessandria 5
Collegno 5
Delhi 5
Greifswald 5
Memphis 5
Santa Clara 5
Villanova 5
Baotou 4
Dallas 4
Guadalajara 4
Jersey City 4
Jinan 4
Rome 4
Surbo 4
Wuhan 4
Xian 4
Zurich 4
Auburn Hills 3
Basel 3
Bengaluru 3
Bologna 3
Brno 3
Cranston 3
Frankfurt am Main 3
Helsinki 3
Totale 5886
Salva come PNG Salva come JPEG
Nome #
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 557
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents 275
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 185
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report 176
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib 176
Can pegylated interferon improve the outcome of polycythemia vera patients? 163
FLAI induction regimen in elderly patients with acute myeloid leukemia 160
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 144
Anemia in the Elderly: not Always what it Seems. 134
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study 129
Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. 128
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 127
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 126
DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 115
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 113
THE COMBINATION OF FLUDARABINE + CITARABINE + IDARUBICIN (FLAI) IS A SAFE AND EFFECTIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH RISK MDS 111
Hematopoietic stem and progenitor cell composition in peripheral blood and in mobilized CD34+ cells harvests. 108
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 106
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 106
Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation. 102
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 98
Surface phenotypes of human hemopoietic progenitor cells defined by monoclonal antibodies. 97
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 97
Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. Pharmacokinetic and activity studies of single-dose administration in mice. 96
Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients 96
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients 94
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study 93
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 88
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 86
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. 85
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. 83
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE 80
Enhancement of methotrexate cytotoxicity by modulation of proliferative activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line. 78
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation 78
IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS 77
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. 77
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells. 76
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 76
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 75
Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. 75
A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. 74
Trophoblast cell line conditioned medium for in vitro culture and antigenic characterization of acute myeloid leukemia clonogenic cells. 74
Induction of proliferation and NK activity in human lymphocytes by mature myelomonocytic cells: evidence for an HLA-DR-independent MLR stimulatory ability of terminally differentiated nonlymphoid leukemic cell lines and of normal peripheral blood granulocytes. 72
Functional and phenotypic characterization of two HL60 clones resistant to dimethylsulfoxide. 72
A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. 72
Ras oncogene mutation in multiple myeloma. 71
Real life use of bendamustine in elderly patients with lymphoid neoplasia 71
Harlequin granulocyte-colony stimulating factor interleukin 6 molecules with bifunctional and antagonistic activities. 68
Establishment from an adult leukemic patient of two novel precursor B cell lines with different growth modality. 68
DIFFERENT COMPOSITION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS BETWEEN PERIPHERAL BLOOD AND BONE MARROW: BIOLOGICAL AND CLINICAL IMPLICATIONS 68
Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm. 68
Angiocentric lymphoma: a case report. 67
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial 67
A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. 66
Human granulocyte surface molecules identified by murine monoclonal antibodies. 65
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 65
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 64
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. 64
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 63
A novel human lymphokine that inhibits haematopoietic progenitor cell proliferation. 63
Stem cell factor improvement of proliferation and maintenance of hemopoietic progenitors in myelodysplastic syndromes. 62
A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib. 62
COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) 61
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients 61
Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. 60
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 60
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs 59
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. 58
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 58
[Variability of the response to recombinant human erythropoietin in patients undergoing hemodialysis treatment] 57
Induction of differentiation of HL-60 cells by dimethyl sulfoxide: evidence for a stochastic model not linked to the cell division cycle. 57
Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. 57
Immunological separation of two CFU-GM subsets showing different responsiveness to T-cell derived growth factors. 57
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 57
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 56
Surface phenotype of clonogenic cells in acute myeloid leukemia defined by monoclonal antibodies. 56
Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. 55
Subpopulation heterogeneity in human acute myeloid leukemia determined by monoclonal antibodies. 55
Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline 54
Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. 54
Self-renewal inhibition of acute myeloid leukemia clonogenic cells by biological inducers of differentiation. 53
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib 53
Dedifferentiation , maldifferentiation or arrested differentiation in human acute myelogenous leukemia. 52
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia 52
Cyclic neutropenia and severe hypogammaglobulinemia in a patient with excess of CD8-positive T lymphocytes: response to G-CSF therapy. 51
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 51
In patients with Polycythemia Vera older age is the prognostic factor at highest impact on survival 51
Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow. 51
Human recombinant stem cell factor stimulates in vitro proliferation of acute myeloid leukemia cells and expands the clonogenic cell pool. 50
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 50
Sensibilita' delle sottopopolazioni staminali mieloidi (CFU-GM) a CSA di diversa origine. 49
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience 49
Human leukaemic cell lines 48
Responsiveness of highly enriched CFU-GM subpopulations from bone marrow, peripheral blood, and cord blood to hemopoietic growth inhibitors. 48
Increase of telomerase activity and hTERT expression in myelodysplastic syndromes 48
CD9 antigen on acute non-lymphoid leukemia cells: preferential expression by promyelocytic (M3) subtype. 48
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 48
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 47
Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response 46
Induction of differentiation of human myeloid leukemias by phorbol diesters: phenotypic changes and mode of action. 45
Totale 8454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18413
article - articoli 0
book - libri 0
conference - conferenze 3803
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201815 0000 00 00 00015
2018/2019734 31174423 3183 38135 235020059
2019/20201527 454078111 108286 170100 2651619469
2020/20211289 1207111756 11158 8765 17796125206
2021/20221404 656643109 4338 15173 43120313340
2022/20232611 24217652193 185574 214137 1995121270
Totale 10024